Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy.
ABCB1
ABCC2
ALDH1A1
anthracyclines
ifosfamide
neoadjuvant
pharmacogenetics
soft tissue sarcoma
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
11 Apr 2022
11 Apr 2022
Historique:
received:
14
03
2022
accepted:
07
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Neoadjuvant chemotherapy based on anthracyclines and ifosfamide for high-risk soft tissue sarcomas (STS) of the extremities and trunk is a controversial treatment option. There are substantial interindividual differences in clinical outcomes in patients treated with neoadjuvant chemotherapy. The aim of this study was to evaluate, as biomarkers, polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, or drug targets and their association with toxicity and survival in STS patients treated with neoadjuvant chemotherapy. We analysed variants in genes involved in anthracycline metabolism (
Identifiants
pubmed: 35455734
pii: jpm12040618
doi: 10.3390/jpm12040618
pmc: PMC9024670
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmacogenomics J. 2010 Feb;10(1):62-9
pubmed: 19752884
Br J Cancer. 2010 Mar 16;102(6):1003-9
pubmed: 20179710
Biol Pharm Bull. 2008 Nov;31(11):2137-42
pubmed: 18981587
Eur J Pharm Sci. 2004 Jan;21(1):25-51
pubmed: 14706810
Pharmacogenet Genomics. 2011 Jul;21(7):440-6
pubmed: 21048526
Mod Pathol. 2012 Mar;25(3):388-97
pubmed: 22080062
Sci Rep. 2017 Apr 19;7:46537
pubmed: 28422153
Pharmacogenomics J. 2019 Aug;19(4):390-400
pubmed: 30237583
PLoS One. 2011;6(10):e26091
pubmed: 22016816
Biochim Biophys Acta. 2009 May;1794(5):860-71
pubmed: 19285158
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Pharmacogenomics. 2016 Feb;17(3):231-40
pubmed: 26799497
J Biol Chem. 1996 May 17;271(20):11884-90
pubmed: 8662658
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Pharmacogenet Genomics. 2014 Feb;24(2):133-8
pubmed: 24401834
Pharmacogenet Genomics. 2011 Dec;21(12):808-19
pubmed: 21946896
Pharmacogenomics. 2009 Mar;10(3):489-93
pubmed: 19650256
Chem Biol Interact. 2001 Jan 30;130-132(1-3):209-18
pubmed: 11306045
Pharmacogenomics J. 2007 Feb;7(1):56-65
pubmed: 16788565
Biochem Biophys Res Commun. 2005 Aug 5;333(3):754-62
pubmed: 15963465
Am Soc Clin Oncol Educ Book. 2018 May 23;38:910-915
pubmed: 30231383
J Clin Oncol. 2009 Jun 1;27(16):2604-14
pubmed: 19349540
Pharmacogenet Genomics. 2008 Apr;18(4):357-65
pubmed: 18334920
Pharmacogenomics J. 2015 Aug;15(4):372-9
pubmed: 25582575
Pharmacology. 2000 Sep;61(3):192-8
pubmed: 10971205
Onco Targets Ther. 2020 Feb 17;13:1413-1419
pubmed: 32110040
N Engl J Med. 2015 Sep 3;373(10):895-907
pubmed: 26287746
Pharmacogenet Genomics. 2008 Jul;18(7):621-31
pubmed: 18551042
PLoS One. 2014 Dec 29;9(12):e116027
pubmed: 25545243
Front Pharmacol. 2020 Jun 30;11:973
pubmed: 32695000
Cancer Sci. 2008 Apr;99(4):816-23
pubmed: 18377430
Eur J Cancer. 2016 Jan;53:84-95
pubmed: 26700077
Nat Genet. 2008 Jul;40(7):844-53
pubmed: 18511948
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Hum Gene Ther. 1998 Mar 20;9(5):611-9
pubmed: 9551609
Alcohol Clin Exp Res. 2011 Feb;35(2):304-16
pubmed: 21083667
Oncotarget. 2018 Jan 10;9(10):9114-9136
pubmed: 29507678
Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1201-10
pubmed: 21919804
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
N Engl J Med. 2003 Feb 6;348(6):538-49
pubmed: 12571262
Pharmacogenomics J. 2014 Jun;14(3):241-7
pubmed: 23999597
Curr Drug Metab. 2010 Jan;11(1):115-28
pubmed: 20302569
Pharmacogenet Genomics. 2017 Oct;27(10):378-385
pubmed: 28763429
Pharmacogenet Genomics. 2008 May;18(5):383-9
pubmed: 18408561
Drug Metab Pharmacokinet. 2015 Apr;30(2):149-53
pubmed: 25989890